Nipro Corporation (TYO:8086) has announced the completion of a short form merger between its subsidiary, Nippon Product Acquisition Corporation and Home Diagnostics, Inc. (NASDAQ:HDIX). Nippon Product Acquisition Corporation has now merged with and into Home Diagnostics. Home Diagnostics has survived the merger and will continue as a wholly owned subsidiary of Nipro. All Home Diagnostics shares are not tendered under the terms of the tender offer. All trading of Home Diagnostics on the Nasdaq Global Select Market have ceased.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
NIPRO CORPORATION is a Japan-based company engaged in the manufacture of medical devices, pharmaceutical products and medical and glass products. The Company operates in four business divisions. The Medical Device division is engaged in the manufacture and sale of medical devices and its related products, the development, manufacture and sale of cell culturing-related products, as well as the development and sale of diabetes-relates products. The Pharmaceutical division is engaged in the research, manufacture and sale of pharmaceuticals, such as blood derivatives. The Instrument division is engaged in the manufacture and sale of glass pipes and other glass products, including the inner bottles of thermos bottles. The Others division is engaged in the sale of medical device manufacturing equipment, the leasing of real estate and the non-life insurance agency business.
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
